BiomX Virtual KOL Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections
About The Event
Join BiomX for a virtual KOL event, featuring Dr. Eitan Kerem, M.D. (Hadassah University Medical Center) and Dr. Robert T. “Chip” Schooley, M.D. (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections. P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.
A live question and answer session will follow the formal presentations.